赤痢菌ワクチンの世界市場-2023年～2030年

概要

赤痢菌ワクチンは、中等度から重度の下痢や赤痢を引き起こす可能性のある赤痢菌によって引き起こされる赤痢症を予防するために設計されたワクチンです。赤痢菌ワクチンの開発は公衆衛生にとって重要な目標であり、抗生物質の使用を減らし、結果として抗菌薬耐性の出現を抑えるという間接的な効果をもたらす可能性があります。

赤痢菌には4つの菌種があり、そのうち3つの菌種には複数の血清型があります。このように多くの血清型が存在するため、免疫学的防御は主に血清型特異的であり、ワクチン開発にとって課題となります。Shigella flexneriは、特に低所得国において世界的に最も重要な菌種であり、15の血清型から構成されています。最も一般的なものがS. flexneri 2aで、続いて3a、6となっています。

Shigella sonneiの血清型は1つだけで、工業開発が進んでいる国々では支配的な菌種です。赤痢菌には15の血清型ですが、最も重要なのは赤痢菌1型で、致死率の高い流行アウトブレイクの原因となりましたが、21世紀には消滅したと思われます。19の血清型を持つShigella boydiiは、赤痢症例のごく少数の原因となっており、主に南アジアで検出されています。

市場力学：市場促進要因と市場抑制要因

新たなワクチンパイプライン

有効性と安全性の高い赤痢菌ワクチンが開発されれば大きな成果ですが、予防接種スケジュールが混み合い、競合する他の治療法も数多くある中で、こうしたワクチン自体が売れることはないと思われます。ワクチンの推奨、購入、採用に必要な政治的意思や草の根の支持を喚起するのに役立つ、説得力のある公衆衛生上の価値提案があるかどうかを見極めるには、まだやるべきことがあります。

市場力学：市場抑制要因

ワクチンの副作用は、予測期間中の市場成長を妨げる主な要因のひとつです。副作用には、接種部位の痛みや腫れ、発熱、騒ぐ、食欲不振、倦怠感、嘔吐などがあります。インフルエンザ生ワクチンの場合、嘔吐、筋肉痛、発熱、のどの痛み、咳なども起こりうる副作用です。これらの副作用が市場の成長を制限しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新たなパイプラインワクチン
  • 抑制要因
    • ワクチンに伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 ワクチンタイプ別

• 生ワクチン
• 不活化ワクチン
• 全細胞不活化ワクチン
• サブユニット不活化ワクチン
• 結合型ワクチン
• その他

第8章 年齢層別

• 乳児
• 小児

第9章 エンドユーザー別

• 病院
• 診療所
• 非政府組織（NGO）
• 予防接種センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• LimmaTech Biologics AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Eveliqure Biotechnologies GmbH
• Zhi Fei Biological
• Vaxcyte
• Inventprise（*LIST NOT EXHAUSTIVE）

第13章 付録

Overview

A Shigella vaccine is a vaccine designed to prevent shigellosis, a Vaccine caused by the shigella bacteria that can lead to moderate-to-severe diarrhoea and dysentery. The development of a Shigella vaccine is an important goal for public health, as it could have indirect effects on reducing the use of antibiotics and the consequent emergence of antimicrobial resistance.

There are four species of shigella, and three of these have multiple serotypes. This large number of Shigella serotypes presents a challenge for vaccine development since immunologic protection is largely serotype-specific. Shigella flexneri is the most important species globally, particularly in low-income countries, and consists of 15 serotypes, the most common of which is S. flexneri 2a, followed by 3a and 6.

Shigella sonnei has just one serotype and is the dominant species in countries that are undergoing industrial development. Shigella dysenteriae has 15 serotypes, the most significant being Shigella dysenteriae type 1, which was responsible for epidemic outbreaks with high-case fatality rates that seem to have disappeared in the 21st century. Shigella boydii, which has 19 serotypes, is responsible for a small minority of shigellosis cases and is mainly detected in South Asia.

Market Dynamics: Drivers and Restraints

Emerging vaccine pipeline

The development of highly effective and safe shigella vaccines would be a major accomplishment, but these vaccines will not sell themselves in the context of a crowded immunization schedule and many other competing interventions. There is still work to be conducted to determine if there is a compelling public health value proposition that can help stimulate the political will and grassroots advocacy often necessary for vaccine recommendations, purchase, and adoption.

Market Dynamics: Restraint

Side effects of vaccines are one the key factors that hamper the market growth during the forecast period. Some of the side effects include soreness or swelling where the shot was given, fever, fussiness, loss of appetite, tiredness, and vomiting. In the case of Influenza live vaccine, vomiting, muscle aches, fever, sore throat, and cough are other possible side effects. These side effects are limiting the market growth.

Segment Analysis

The global shigella vaccine pipeline is segmented based on vaccine type, age group, end-user and region.

The live attenuated vaccines from the vaccine type segment accounted for approximately 42.2% of the market share

The live attenuated vaccines from the vaccine type segment accounted for approximately 42.2% and it is expected to be dominated during the forecast period. Live attenuated vaccines are designed using weakened or attenuated forms of the pathogen. In the case of Shigella vaccines, live attenuated strains of the bacteria are used. These attenuated strains have been modified so that they are less virulent (less capable of causing Vaccine) compared to the wild-type, or naturally occurring, strains of Shigella.

For instance, according to clinical trails.gov on October 12, 2022, National Institute of Allergy and Infectious Vaccines (NIAID) started a clinical study on A Double-Blind Placebo-Controlled Randomized Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. sonnei 53G in Healthy Adults where it is currently under Phase 2 trials and estimated to complete its studies by July 2024.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors like ongoing clinical trials, improved healthcare infrastructure in this region, research and development activities and a large number of biotechnological companies. The development of products and approval of vaccine products helps this region to have the highest market share during the forecast period.

For instance, according to clinicaltrial.gov on September 29, 2022, the University of Maryland, Baltimore started a clinical studies on Study of the Safety, Tolerability, and Immunogenicity of Oral Doses of CVD 1208S-122, a Prototype Attenuated Shigella Flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia Coli Antigens which is currently under phase 1 and this clinical trials are taking place in United States and studies are estimated to complete by September 2024.

COVID-19 Impact Analysis

There is limited information on the impact of COVID-19 on Shigella vaccines. However, existing COVID-19 booster vaccines are expected to provide reasonable protection against the virus. The development of a Shigella vaccine is an important goal for public health, as shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering

Market Segmentation

By Vaccine Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Whole-cell inactivated vaccines
• Subunit inactivated vaccines
• Conjugate Vaccines
• Others

By Age Group

• Infants
• Childrens

By End User

• Hospitals
• Clinics
• Non-Governmental Organizations (NGOs)
• Vaccination Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the shigella vaccine pipeline market include: LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Zhi Fei Biological, Vaxcyte, Inventprise and among others.

Key Developments

• In July 2023, GSK licensed out its Shigella vaccine candidate to LimmaTech Biologics, giving the Swiss biotech rights to further develop and eventually commercialize the quadrivalent bioconjugate investigational vaccine, LimmaTech is aiming to complete the Phase I/II clinical trial for this quadrivalent candidate and post data from this study within the year.
• In November 2020, Eveliqure announced the publication of key preclinical data for its clinical-stage vaccine candidate against Shigellosis and ETEC.

Why Purchase the Report?

• To visualize the global shigella vaccine pipeline market segmentation-based vaccine type, age group, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous shigella vaccine pipeline market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key vaccines of all the major players.

The global shigella vaccines pipeline market report would provide approximately 46 tables, 56 figures, and 165 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Vaccine Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Driver
    • 4.1.1.1. Emerging pipeline vaccines
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the vaccines
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Vaccine Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 7.1.2. Market Attractiveness Index, By Vaccine Type
• 7.2. Live Attenuated Vaccines *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Inactivated Vaccines
• 7.4. Whole-cell inactivated vaccines
• 7.5. Subunit inactivated vaccines
• 7.6. Conjugate Vaccines
• 7.7. Others

8. By Age Group

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 8.1.2. Market Attractiveness Index, By Age Group
• 8.2. Infants *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Children

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Clinics
• 9.4. Non-Governmental Organizations (NGOs)
• 9.5. Vaccination Centers
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. LimmaTech Biologics AG
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Eveliqure Biotechnologies GmbH
• 12.3. Zhi Fei Biological
• 12.4. Vaxcyte
• 12.5. Inventprise (*LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us